{"cluster": 46, "subcluster": 5, "abstract_summ": "While such cardiac events may occur, for example, in all-cause CAP and CAP due to influenza virus infection, and more recently described with the SARS-CoV-2 pandemic, a significant amount of research work has been investigating the pathogenic mechanisms of these cardiac events in patients with CAP due to Streptococcus pneumoniae (pneumococcus) and, more recently, COVID-19 infections.RESULTS: Notably, COVID\u201019 patients with pre\u2010existing cardiovascular disease are counted in greater frequency in intensive care unit settings, and ultimately suffer greater rates of mortality.Finally, patients with baseline QT prolongation or those taking QT prolonging drugs must be cautious when treating with lopinavir/ritonavir and hydroxychloroquine for COVID-19.BACKGROUND: Respiratory complications have been well remarked in the novel coronavirus disease (SARS\u2010CoV\u20102/COVID\u201019), yet an emerging body of research indicates that cardiac involvement may be implicated in poor outcomes for these patients.Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19.Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19.", "title_summ": "Management of Acute Myocardial Infarction During the COVID-19 PandemicCOVID-19 Cardiac Injury: Implications for Long-Term Surveillance and Outcomes in SurvivorsCardiovascular disease management during the coronavirus disease 2019 pandemicCardiac involvement in COVID\u201019 patients: Risk factors, predictors, and complications: A reviewCardiac complications in community-acquired pneumonia and COVID-19Management of Acute Myocardial Infarction During the COVID-19 Pandemic.", "title_abstract_phrases": "While such cardiac events may occur, for example, in all-cause CAP and CAP due to influenza virus infection, and more recently described with the SARS-CoV-2 pandemic, a significant amount of research work has been investigating the pathogenic mechanisms of these cardiac events in patients with CAP due to Streptococcus pneumoniae (pneumococcus) and, more recently, COVID-19 infections.Finally, patients with baseline QT prolongation or those taking QT prolonging drugs must be cautious when treating with lopinavir/ritonavir and hydroxychloroquine for COVID-19.Cardiac involvement in COVID\u201019 patients: Risk factors, predictors, and complications: A reviewBACKGROUND: Respiratory complications have been well remarked in the novel coronavirus disease (SARS\u2010CoV\u20102/COVID\u201019), yet an emerging body of research indicates that cardiac involvement may be implicated in poor outcomes for these patients.Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19.Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19.Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating a ST-elevation MI presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread."}